U.S. Markets open in 3 hrs 22 mins
  • Crude Oil

    70.51
    -0.05 (-0.07%)
     
  • Gold

    1,776.30
    -1.90 (-0.11%)
     
  • Silver

    22.53
    -0.04 (-0.17%)
     
  • EUR/USD

    1.1733
    +0.0003 (+0.0235%)
     
  • 10-Yr Bond

    1.3240
    0.0000 (0.00%)
     
  • Vix

    22.93
    -2.78 (-10.81%)
     
  • GBP/USD

    1.3636
    -0.0028 (-0.2045%)
     
  • USD/JPY

    109.5210
    +0.3010 (+0.2756%)
     
  • BTC-USD

    44,590.88
    -3,435.44 (-7.15%)
     
  • CMC Crypto 200

    1,056.81
    -7.03 (-0.66%)
     
  • FTSE 100

    7,062.01
    +81.03 (+1.16%)
     
  • Nikkei 225

    29,639.40
    -200.31 (-0.67%)
     

Selecta Biosciences to Participate in Upcoming Investor Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

WATERTOWN, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate virtually in the following investor conferences in November:

Jefferies Virtual London Healthcare Conference
Date: Tuesday, November 17, 2020
Presentation time: 9:05 a.m. ET

Stifel 2020 Virtual Healthcare Conference
Date: Wednesday, November 18, 2020
Fireside chat time: 2 p.m. ET

Live webcasts will be available in the Investors & Media section of the company’s website at www.selectabio.com.

About Selecta Biosciences, Inc.
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With an observed ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body’s natural self-tolerance in autoimmune diseases. The company’s first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in collaboration with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi. For more information, please visit www.selectabio.com

For Investors:
Lee M. Stern
Solebury Trout
+1-646-378-2922
lstern@soleburytrout.com

For Media:
Meredith Sosulski, Ph.D.
LifeSci Communications, LLC
+1-929-469-3851
msosulski@lifescicomms.com